FDA issues warning to Lancome

Published: 14-Sep-2012

Warning relates to misleading publicity over Genefique line


The US drugs and medicines regulatory agency, the FDA, has issued a warning to L'Oréal and its American subsidiary Lancôme alleging misleading publicity for certain anti-wrinkle products included in the company's Genefique Youth Activate Concentrate line.

The FDA's view is that the promotion suggests that these products can "modify the structure or function of the human body" which would put them in the category of medicines or drug products under US law. The L'Oréal products in the agency's spotlight are all sold online or in the cosmetics departments of the major stores.

The French group was given 15 days to come up with measures to correct the situation and the FDA has demanded that L'Oréal takes steps to eliminate the breaches of law linked to these products.

You may also like